financetom
Business
financetom
/
Business
/
Wheaton Precious Metals Up 1.4% After Hours as It Reports a Higher Q4 Adjusted Profit, Hikes Dividend
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wheaton Precious Metals Up 1.4% After Hours as It Reports a Higher Q4 Adjusted Profit, Hikes Dividend
Mar 12, 2026 3:03 PM

05:35 PM EDT, 03/12/2026 (MT Newswires) -- Wheaton Precious Metals ( WPM ) was up 1.5% in after-hours New York trading after the company on Thursday reported higher adjusted profit and revenue for the fourth quarter and hiked its quarterly dividend.

The company's adjusted earnings, excluding most one-time items, rose to US$555 million, or US$1.22 per share, in the period, up from US$199 million, or US$0.44 per share, a year ago. FactSet expected US$1.10 per share.

Revenue rose to US$864.7 million from US$380.5 million a year prior. FactSet projected US$779 million.

The company's quarterly dividend was raised to US$0.195 per share for 2026, an 18% increase from 2025 and the third straight annual increase, the company said.

The company expects 2026 production of 860,000 to 940,000 gold equivalent ounces (GEOs). "This expected year-over-year growth is driven primarily by the additional stream at Antamina, which is expected to add another 70,000 GEOs to the portfolio in 2026 and begin generating production on April 1, 2026," it said.

Long term, production is forecast to increase about 50% to 1.2 million GEOs by 2030, and is expected to remain around 1.2 million ounces annually from 2031 to 2035, the company added.

The company's shares were last seen up US$2.23 to US$147.96 after hours. They closed down C$3.21 to C$198.85 on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Market Chatter: Dell to Start Shipping Servers With New Nvidia AI Chips in November
Update: Market Chatter: Dell to Start Shipping Servers With New Nvidia AI Chips in November
Oct 15, 2024
11:50 AM EDT, 10/15/2024 (MT Newswires) -- (Updates with Nvidia's ( NVDA ) response in the third paragraph.) Dell Technologies ( DELL ) will start shipping servers featuring Nvidia's ( NVDA ) Blackwell artificial intelligence accelerators to select customers next month, Bloomberg reported Tuesday, citing an interview with Arthur Lewis, Dell's infrastructure unit president. The servers containing the Blackwell chips...
SoFi And Nova Credit Boost Partnership, New Cash Flow Analytics To Transform Loan Approvals
SoFi And Nova Credit Boost Partnership, New Cash Flow Analytics To Transform Loan Approvals
Oct 15, 2024
SoFi Technologies, Inc. ( SOFI ) shares are trading higher on Tuesday. The company expanded its multi-year partnership with Nova Credit. This enhancement allows SoFi to access consumer-permissioned bank data and cash flow analytics via Nova Credit’s Cash Atlas solution, enabling the company to better serve its members. Traditional credit reporting evaluates repayment history, while cash flow data provides a...
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Oct 15, 2024
Jazz Pharmaceuticals plc ( JAZZ ) revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG’s (OTC:RHHBY) atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of Zepzelca and atezolizumab showed...
BriaCell to Complete Patient Enrollment for Phase 3 Breast Cancer Study by Mid-2025; Shares Rise
BriaCell to Complete Patient Enrollment for Phase 3 Breast Cancer Study by Mid-2025; Shares Rise
Oct 15, 2024
11:49 AM EDT, 10/15/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday that patient enrollment for its pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer is on track for expected completion by mid-2025. The trial aims to enroll up to 354 patients, randomized 1:1 to receive either the BriaCell...
Copyright 2023-2026 - www.financetom.com All Rights Reserved